Long-term central venous catheters are required for the administration of antineoplastic agents, antibiotics, total parenteral nutrition, blood components, and intravenous fluids in patients undergoing bone marrow (BM) or peripheral blood stem cell (PBSC) transplantation. Hickman catheters have been generally inserted into the right atrium or superior vena cava via the jugular or subclavian vein. 1, 2 In some patients, such as those with thrombosis of the subclavian veins or mediastinal tumors, insertion of the central venous catheter into the upper part of the body may be difficult or contraindicated. 3 Anecdotally, these catheters were placed in the inferior vena cava using saphenous or femoral veins even in severely immunocompromised patients. 4 The latter includes patients given BM or PBSC transplants where infections are known to be a major risk. 5 Here, we report a 36-year-old female lymphoma patient who had a Hickman catheter inserted by way of the femoral vein, for allogeneic peripheral blood stem cell transplantation (PBSCT). She experienced recurrence of high-grade non-Hodgkin's lymphoma with bulky mediastinal disease and lung involvement. Despite conventional-dose chemotherapy her disease progressed. Therefore, surgical resection of both upper lobes of the lungs and parts of the sternum was performed. Afterwards, she was referred to our institution for PBSCT from her human leukocyte antigenidentical brother. Because of thrombosis of both subclavian and brachiocephalican veins, the right internal jugular vein, and the superior vena cava above the level of the azygos vein, the patient was unable to have a central venous catheter sited in the upper part of the body. Therefore, a double lumen Hickman catheter (Bard, Access Systems, Salt Lake City, UT, USA) was inserted into the inferior vena cava by way of the femoral vein under strictly aseptic conditions and after local anesthesia. After establishing that there was good blood return the catheter was flushed with heparinized saline solution (each lumen with 2 ml saline with 500 units of heparin) and capped. The exit site was dressed with providine-iodine ointment and a dry sterile dressing which was changed daily during hospitalization. The catheter exit site was inspected by a nurse on a daily basis during the hospital stay. All intravenous fluids, parenteral nutrition, antibiotics, irradiated blood products, and PBSCs were administered through this catheter and all diagnostic blood samples were obtained from there.
After conditioning with busulfan and cyclophosphamide 21.5 × 10 6 CD34-positive peripheral blood stem cells/kg body weight from her sibling donor were infused, obtained after granulocyte colony-stimulating factor stimulation by leukapheresis. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A (CsA) starting 1 day before stem cell infusion. Absolute neutrophil counts (ANC) above 0.5 × 10 9 /l and unsupported platelet counts above 20 × 10 9 /l were achieved 11 and 8 days after stem cell grafting. Because of fever of unknown origin, empirical broad-spectrum antimicrobial therapy was given resulting in resolution of fever within 3 days. On day +34 the patient was discharged from the hospital without signs of GVHD or infection. The catheter dressing was then changed twice a week by the patient, who had been carefully instructed in sterile handling of the line. Each lumen was flushed with 10 ml saline followed by 2 ml heparinized saline (500 units/ml) after every use or routinely once a month in the outpatient clinic. About 2 months after PBSCT, cytomegalovirus reactivation occurred, requiring pre-emptive therapy with gancyclovir. Two weeks later (day +82 after PBSCT) a Staphylococcus epidermidis bacteremia led to removal of the central venous catheter. The infection promptly resolved with appropriate antibacterial therapy. No further infections were observed in the follow-up period after PBSCT.
To our knowledge, few BM recipients with central venous catheters inserted in the inferior vena cava by way of the external iliac or femoral vein have been reported to date, 4 when increased infection rates of 30% to 40% with a 17% incidence of septicemia were observed. Since the latter was caused both by gram-positive and gram-negative organisms, broad-spectrum antimicrobial therapy was required in these patients. In patients with Hickman catheters in the upper parts of the body, infection rates of 9% to 15% with different incidences of mainly gram-positive septicemia have been reported. 6, 7 Catheters remained in the groin area for a median of 30 days. 4 In our patient, the Hickman catheter was used successfully despite profound neutropenia and severe immunosuppression for 3 months without serious infectious or thrombotic complications. The latter have been reported in 6% of patients with iliac vein catheters which is not significantly different from thrombotic complications in patients with subclavian venous cannulation. 7 In summary, central venous catheters can be inserted and maintained in the groin area, even in severely immunocompromised stem cell transplant patients, when catheters cannot be placed in tributaries of the superior vena cava. However, extensive supportive care including daily redressing of the catheter exit site during hospitalization using a strict aseptic technique is recommended to decrease the risk of infection and to allow prolonged use of the central venous catheter. 
Safety of high-dose Amphotericin B lipid complex
Infection with Aspergillus species carries a high mortality in patients with liver disease, 1,2 and amphotericin B remains the agent of choice for the treatment of aspergillus infections. Lipid-based formulations of amphotericin B are less toxic than the conventional form of the drug. 3 Amphotericin B lipid complex (Abelcet) is a lipid formulation with a high amphotericin B/lipid ratio (1:1). 4 Pharmacokinetic studies indicate that this formulation achieves lower peak plasma concentrations, but higher tissue levels than the other lipid formulations of amphotericin B (liposomal amphotericin B (AmBisome) and amphotericin B colloidal dispersion). 5 Clinical analyses suggest that Abelcet is a safe and effective agent for the treatment of invasive fungal infection (IFI).
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Ringdén et al 10 report a high rate of toxicity associated with the use of high-dose Abelcet in a mixed group of critically ill patients. In their retrospective review, 19 patients received Abelcet at a mean dose of 4.1 mg/kg once daily, and 14 (74%) suffered side-effects requiring discontinuation of the drug. They acknowledge that side-effects of Abelcet were rarely seen in other analyses, 8, 9 and they encourage others to report their experiences with this drug.
In the Birmingham Liver Unit, during an 18 month period commencing November 1996, we treated 30 patients (10 male, 20 female; median age 49.5 years, range 20-68 years) with Abelcet at 5 mg/kg once daily (32 treatment episodes).
Eighteen patients underwent 20 liver transplants (LT) (underlying diagnoses: primary biliary cirrhosis, seven; fulminant hepatic failure, three; retransplantation, three; hepatitis C virus cirrhosis, three; primary sclerosing cholangitis, two; hepatitis B virus cirrhosis/hepatoma, one; cryptogenic cirrhosis, one), and received Abelcet (20 treatment episodes) following LT. Of these, 11 treatment episodes were part of a prospective audit to assess drug safety and efficacy as prophylaxis post-LT (unpublished data). The reasons for the other nine treatment episodes were: IFI in two, suspected IFI in two, and at risk for IFI (empirical) in five.
The other 12 patients (diagnoses: post-hepatobiliary/ pancreatic surgery, four; acute liver failure or advanced liver disease, eight) received 12 treatment episodes with Fifteen of 30 patients died, but no deaths were attributed to Abelcet. No adverse reactions were observed in 24 of 30 patients receiving Abelcet. The drug was discontinued in three of 30 patients because of fever and chills, but it was restarted 2 days later in one of these patients, who went on to receive a further eight doses without complication. Thus, Abelcet was permanently discontinued in only two of 30 patients (6.7%), and in both patients symptoms resolved following administration of antihistamine and corticosteroid. Note that this compares with a 74% discontinuation rate reported by Ringdén et al. 10 Of these two patients, one was converted to fluconazole, but died of cryptococcal meningitis 8 days later. The other patient was converted initially to fluconazole, then to AmBisome and finally to conventional amphotericin B, but died of probable Candida peritonitis 1 month later. Three other patients experienced fever and chills; of these, symptoms improved in one patient following treatment with antihistamine and corticosteroid. Symptoms in the other two patients did not require treatment and improved with subsequent doses of Abelcet. These two patients received a further two and eight doses of Abelcet, respectively. Diminution of symptoms with successive doses of Abelcet has previously been documented. 9 We did not observe any renal toxicity which was temporally related to Abelcet administration. For all 32 treatment episodes, mean serum creatinine level was 197 Ϯ 21 mol/l (mean Ϯ s.e.) before and 191 Ϯ 15 mol/l at the end of Abelcet, P = 0.74 (NS), t-test for paired samples. For cases receiving cyclosporine or tacrolimus (n = 20), the corresponding values were 187 Ϯ 25 mol/l before and 187 Ϯ 16 mol/l at the end of Abelcet, P = 0.99 (NS); for the remaining 12 cases the values were 215 Ϯ 37 mol/l before and 196 Ϯ 31 mol/l
